Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.

@article{LindhoffLast2013LaboratoryTO,
  title={Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.},
  author={Edelgard Lindhoff-Last and J. I. Ansell and Theodore Erich Spiro and Meyer Michel Samama},
  journal={Annals of medicine},
  year={2013},
  volume={45 5-6},
  pages={423-9}
}
A number of target-specific oral anticoagulants (TSOAs) have been developed in recent years, and some have shown considerable promise in large-scale, randomized clinical trials in the prevention and treatment of thromboembolism. Unlike traditional anticoagulants, such as vitamin K antagonists, these TSOAs exhibit predictable pharmacokinetics and pharmacodynamics. Among these agents, rivaroxaban, a direct Factor Xa inhibitor, has been approved for clinical use in many countries for the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS